Identification of BCR::ABL1 Mutations by Digital PCR in CML

计划入组 150 人 · 首次发布于 2025 年 9 月 5 日

The Evaluation and Comparison of BCR-ABL p210 mRNA Transcripts (%IS Unit) Results Between Dr. PCR™ BCR-ABL1 Major IS Detection Kit (Optolane) and QXDx™ BCR-ABL %IS Kit (Bio-Rad) in Chronic Myeloid Leukemia Patients

计划入组 80 人 · 首次发布于 2024 年 3 月 8 日

Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

计划入组 32 人 · 首次发布于 2022 年 4 月 1 日

Asciminib(Scemblix)

C₂₀H₁₈ClF₂N₅O₃

BCR-ABL(Theseus)

Bcr-Abl kinase inhibitors (Pfizer Global Research and Development)

Exelixis, Inc.

United States

Inhibikase Therapeutics

United States

Regeneron Pharmaceuticals

United States

FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid Leukemia

Novartis Receives CDSCO Approval for Phase IIIb Trial of Asciminib in Chronic Myeloid Leukemia

FDA Approves Scemblix (asciminib) for First-Line Treatment of Chronic Myelogenous Leukemia